Abstracts Archive - Page 246 of 1683 - ATC Abstracts

2021 American Transplant Congress
Donor Derived Cell Free Dna: Teasing Out the Optimal Threshold for Antibody Mediated Rejection
M. Mattu¹, H. Murad¹, M. Merzkani¹, A. Malone¹, R. Delos Santos¹, M. Wang², B. Wang², S. Chang², T. Alhamad¹
¹Department of Medicine, Washington University in St Louis, St Louis, MO, ²Washington University in St Louis, St Louis, MO
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) assay is a putative noninvasive marker for renal allograft rejection and other etiologies of injury such as BK nephropathy. The…
2021 American Transplant Congress
Higher Calcineurin Inhibitor Levels Associate with Graft Outcomes in Kidney Recipients with De Novo Donor-specific Antibodies of Either Hla Class I or II
M. Béland, S. De Serres
Nephrology, CHU de Québec- Université Laval, Québec, QC, Canada
*Purpose: The development of de novo anti-HLA donor specific antibodies (dnDSA) is associated with poorer outcomes in kidney transplant recipients. We and other previously reported…
2021 American Transplant Congress
Hypercholesterolemia and Donor Age Impaired Capillary Vegf and Nitric Oxide (no) Expression and in Turn Decrease Both Microvascular Density and Tubule Villin Expression in Renal Allografts, Resulting in Poor Graft Survival
B. Ozdemir¹, E. Akcay¹, A. Ok Atilgan¹, M. Haberal²
¹Department of Pathology, Baskent University, Ankara, Turkey, ²Division of Transplantation, Department of General Surgery, Baskent University, Ankara, Turkey
*Purpose: The role of aging and hypercholesterolemia (HC) on endothelial cells (ECs) are not well defined. Aged ECs might produce less NO and VEGF, resulting…
2021 American Transplant Congress
HLA Allele Association with Recurrent Iga Nephropathy After Kidney Transplantation
O. Alzahabi, M. Merzkani, H. Murad, A. Java, R. Delos Santos, T. Alhamad, A. Malone
Transplant, Washington University, Saint Louis, MO
*Purpose: IgA nephropathy is one of the most common glomerulonephritis after kidney transplantation. The association of IgA nephropathy recurrence with recipient HLA typing is not…
2021 American Transplant Congress
Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: Phase 3 IMAGINE Study Design
P. Nickerson¹, G. Böhmig², S. Chadban³, D. Kumar⁴, R. B. Mannon⁵, T. van Gelder⁶, S. Adler⁷, E. Chong⁷, A. Djamali⁸
¹University of Manitoba, Winnipeg, MB, Canada, ²Medical University of Vienna, Vienna, Austria, ³University of Sydney, Sydney, Australia, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷CSL Behring, King of Prussia, PA, ⁸University of Wisconsin, Madison, WI
*Purpose: Chronic active antibody-mediated rejection (CAMR) is a major cause of allograft loss with no approved drugs for its treatment. Currently, off-label regimens recommended by…
2021 American Transplant Congress
Cancer Among Kidney Transplant Recipients More Than 20 Years After Transplantation: PTLD Remains the Most Common Cancer Type Even in the Very Long-Term
T. Schachtner, J. Fuhrmann, T. Mueller
Nephrology, University Hospital Zurich, Zurich, Switzerland
*Purpose: Due to an improved patient and kidney allograft survival, cancer is increasingly recognized as the major cause of death after kidney transplantation. Cancer risk…
2021 American Transplant Congress
Outcomes of Kidney Transplantation in Patients with Congenital Anomalies of the Kidney and Urinary Tract
O. A. Oto¹, Y. Caliskan², H. Yazici¹, S. Mirioglu³, A. Dirim¹, N. Garayeva¹, S. Safak¹, E. Demir¹, Y. Ozluk⁴, A. Artan¹, A. Turkmen¹, K. Lentine²
¹Nephrology, Istanbul University, Istanbul, Turkey, ²Nephrology, Saint Louis University School of Medicine, Saint Louis, WA, ³Nephrology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey, ⁴Pathology, Istanbul University, Istanbul, Turkey
*Purpose: We aimed to compare the long-term outcomes after kidney transplantation (KTx) in patients with congenital anomalies of the kidney and urinary tract (CAKUT) versus…
2021 American Transplant Congress
Transplant Center Volume in High-risk Recipient Association with Graft and Patient Survival
M. A. Merzkani, H. Murad, M. Mattu, S. Husami, M. Wang, V. Hu, S. Chang, T. Alhamad
Transplant, Washington University, Saint Louis, MO
*Purpose: Evaluation of high-risk recipients in transplant centers involves an intensive multidisciplinary medical evaluation and requires extensive coordination amongst various teams to follow-up on these…
2021 American Transplant Congress
Donor Derived Cell-free DNA Kinetics Early After Kidney Transplant in Patients with Delayed Graft Function Who Received Kidneys from Donation After Cardiac Death Donors
R. Gumber, M. Abuzeineh, C. Mejia, D. Brennan, F. Naqvi
Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD
*Purpose: Delayed graft function (DGF) may reduce long-term kidney allograft survival due to ischemia-reperfusion injury and rejection. Donor Derived Cell-Free DNA (dd-cfDNA) is proposed to…
2021 American Transplant Congress
Characterization of Chronic Renal Allograft Dysfunction at Single Cell Resolution
C. Kuscu¹, C. Kuscu², A. Shetty³, M. Talwar⁴, J. Eason², D. G. Maluf⁵, V. Mas⁶
¹Surgery, James D Eason Transplant Institute, UTHSC, Memphis, TN, ²Surgery, James D Eason Transplant Institute, Memphis, TN, ³Institute for Genome Sciences, School of Medicine, University of Maryland, Baltimore, MD, ⁴Nephrology, James D Eason Transplant Institute, Memphis, TN, ⁵Surgery, Program in Transplantation - University of Maryland, Baltimore, MD, ⁶Surgery, Division of Surgical Science - University of Maryland, Baltimore, MD
*Purpose: Chronic allograft dysfunction (CAD) is one of the major complications after kidney transplantation. Hereby, we aim to assess the molecular and cellular mechanism of…